Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    DIPSS (Dynamic International Prognostic Scoring System) for Myelofibrosis

    Estimates survival in patients with primary myelofibrosis.
    Favorite
    When to Use

    Do you use the DIPSS in Myelofibrosis and want to contribute your expertise? Join our contributor team!

    ≤65
    0
    >65
    +1
    ≤25
    0
    >25
    +1
    ≥10
    0
    <10
    +2
    <1%
    0
    ≥1%
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    Do you use the DIPSS in Myelofibrosis and want to contribute your expertise? Join our contributor team!

    Formula

    Addition of the selected points:

    Variable

    0 points

    1 point

    2 points

    Age, years

    ≤65

    >65

    --

    White blood cell count, x109/dL

    ≤25

    >25

    --

    Hemoglobin, g/dL

    ≥10

    --

    <10

    Peripheral blood blasts

    <1%

    ≥1%

    --

    Constitutional symptoms

    No

    Yes

    --

    Facts & Figures

    Interpretation:

    DIPSS Score

    Risk category

    Median survival

    0

    Low

    Not reached

    1–2

    Intermediate-1

    14.2 years

    3–4

    Intermediate-2

    4 years

    5–6

    High

    1.5 years

    Dr. Francesco Passamonti

    About the Creator

    Francesco Passamonti, MD, is the head of the hematology department at the Circolo Hospital and Macchi Foundation, in Varese, Italy. Previously, he was an assistant professor of hematology at the University of Pavia in Pavia, Italy. Dr. Passamonti’s research focuses primarily on Philadelphia-negative myeloproliferative neoplasms (MPN), polycythemia vera, essential thrombocythemia, and myelofibrosis.

    To view Dr. Francesco Passamonti's publications, visit PubMed